S H Bigner

907 total citations
20 papers, 749 citations indexed

About

S H Bigner is a scholar working on Genetics, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, S H Bigner has authored 20 papers receiving a total of 749 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Genetics, 5 papers in Molecular Biology and 5 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in S H Bigner's work include Glioma Diagnosis and Treatment (6 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Neuroblastoma Research and Treatments (3 papers). S H Bigner is often cited by papers focused on Glioma Diagnosis and Treatment (6 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Neuroblastoma Research and Treatments (3 papers). S H Bigner collaborates with scholars based in United States, Germany and Norway. S H Bigner's co-authors include Carol J. Wikstrand, Darell D. Bigner, Henry S. Friedman, John Q. Trojanowski, P. C. Burger, Edward C. Halperin, Charles N. Pegram, Roger E. McLendon, Nina A. Paleologos and James E. Herndon and has published in prestigious journals such as Journal of Clinical Oncology, Acta Neuropathologica and Journal of Neuropathology & Experimental Neurology.

In The Last Decade

S H Bigner

19 papers receiving 731 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S H Bigner United States 11 342 280 167 141 136 20 749
Bigner Dd United States 11 433 1.3× 390 1.4× 222 1.3× 177 1.3× 84 0.6× 14 821
Ilkcan Cokgor United States 12 277 0.8× 404 1.4× 213 1.3× 157 1.1× 322 2.4× 18 880
Takanori Kamiryo Japan 6 341 1.0× 478 1.7× 200 1.2× 107 0.8× 74 0.5× 7 752
Shoji Shiraishi Japan 10 396 1.2× 601 2.1× 235 1.4× 115 0.8× 85 0.6× 10 947
Noriaki Sugawa Japan 8 544 1.6× 331 1.2× 470 2.8× 151 1.1× 187 1.4× 13 1.1k
Hirofumi Naganuma Japan 22 421 1.2× 237 0.8× 287 1.7× 255 1.8× 80 0.6× 55 1.2k
Shoju Hiraga Japan 13 364 1.1× 175 0.6× 170 1.0× 125 0.9× 43 0.3× 18 696
Y Oda Japan 13 357 1.0× 174 0.6× 212 1.3× 124 0.9× 43 0.3× 21 778
Koji Oka Japan 9 310 0.9× 351 1.3× 227 1.4× 69 0.5× 76 0.6× 23 727
Manfred Westphal Germany 7 303 0.9× 239 0.9× 124 0.7× 204 1.4× 59 0.4× 11 752

Countries citing papers authored by S H Bigner

Since Specialization
Citations

This map shows the geographic impact of S H Bigner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S H Bigner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S H Bigner more than expected).

Fields of papers citing papers by S H Bigner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S H Bigner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S H Bigner. The network helps show where S H Bigner may publish in the future.

Co-authorship network of co-authors of S H Bigner

This figure shows the co-authorship network connecting the top 25 collaborators of S H Bigner. A scholar is included among the top collaborators of S H Bigner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S H Bigner. S H Bigner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bigner, Darell D., Mark T. Brown, Allan H. Friedman, et al.. (1998). Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results.. Journal of Clinical Oncology. 16(6). 2202–2212. 154 indexed citations
2.
Matthew, Susan, et al.. (1998). MOLECULAR AND IMMUNOHISTOLOGIC (IHC) STUDIES ON OLIGODENDROGLIAL (O) TUMORS. Journal of Neuropathology & Experimental Neurology. 57(5). 473–473. 4 indexed citations
3.
Cleveland, Linda, et al.. (1998). Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas.. PubMed. 78(5). 643–4. 30 indexed citations
4.
Rhodes, C. Harker, Katherine M. Call, Marcia L. Budarf, et al.. (1997). Molecular studies of an ependymoma-associated constitutional t(1;22)(p22;q11.2). Cytogenetic and Genome Research. 78(3-4). 247–252. 33 indexed citations
5.
Friedman, H. S., S P Johnson, Qing Dong, et al.. (1997). Methylator resistance mediated by mismatch repair deficiency in a glioblastoma multiforme xenograft.. PubMed. 57(14). 2933–6. 107 indexed citations
7.
Brown, Mark T., R. Edward Coleman, Allan H. Friedman, et al.. (1996). Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results.. PubMed. 2(6). 963–72. 74 indexed citations
8.
Johnston, W W, et al.. (1993). Carcinoma of ovarian and other origins in effusions. Immunocytochemical study with a panel of monoclonal antibodies.. PubMed. 37(4). 439–47. 16 indexed citations
9.
He, Xuanmin, Carol J. Wikstrand, Henry S. Friedman, et al.. (1991). Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts.. PubMed. 64(6). 833–43. 78 indexed citations
10.
Fuller, Gregory N., P. C. Burger, S. Clifford Schold, et al.. (1990). GENE AMPLIFICATION IN HUMAN GLIOMAS. Journal of Neuropathology & Experimental Neurology. 49(3). 320–320. 4 indexed citations
11.
Johnston, W W, et al.. (1990). A panel of antibodies useful in the cytologic diagnosis of metastatic melanoma.. PubMed. 34(3). 385–92. 14 indexed citations
12.
Bigner, S H, Henry S. Friedman, Jaclyn A. Biegel, et al.. (1986). Specific chromosomal abnormalities characterize four established cell lines derived from malignant human gliomas. Acta Neuropathologica. 72(1). 86–97. 19 indexed citations
13.
Friedman, Henry S., P. C. Burger, S H Bigner, et al.. (1985). Establishment and Characterization of the Human Medulloblastoma Cell Line and Transplantable Xenograft D283 Med. Journal of Neuropathology & Experimental Neurology. 44(6). 592–605. 167 indexed citations
14.
Bigner, S H, et al.. (1985). Unusual presentations of inflammatory conditions in cerebrospinal fluid.. PubMed. 29(3). 291–6.
15.
Bigner, S H, et al.. (1985). The cytopathology of reactions to ventricular shunts.. PubMed. 29(3). 391–6. 10 indexed citations
16.
Bigner, S H, P. C. Burger, Joachim Mark, Dennis E. Bullard, & Darell D. Bigner. (1984). 128 RELATIONSHIP BETWEEN KARYOTYPE AND HISTOLOGIC PARAMETERS OF MALIGNANT HUMAN GLIOMAS (MHG). Journal of Neuropathology & Experimental Neurology. 43(3). 335–335. 3 indexed citations
17.
McComb, Rodney D., Carol J. Wikstrand, Mario A. Bourdon, S H Bigner, & Darell D. Bigner. (1983). 10 ANTIGENIC HETEROGENEITY OF HUMAN MALIGNANT GLIOMAS (MGs) DEMONSTRATED BY REACTIVITY WITH 10 MONOCLONAL ANTIBODIES (MCAs). Journal of Neuropathology & Experimental Neurology. 42(3). 308–308. 4 indexed citations
18.
Wallace, R M, S H Bigner, & W W Johnston. (1983). Metastatic breast carcinoma in cerebrospinal fluid. A cytomorphometric study.. PubMed. 26(6). 787–92. 6 indexed citations
19.
Bigner, S H, et al.. (1982). Experimental allergic encephalomyelitis in Lewis rats bearing avian sarcoma virus-induced brain tumors. Journal of Neuroimmunology. 2(3-4). 283–294. 2 indexed citations
20.
Kaminsky, David, et al.. (1980). Diagnostic cytology seminar.. PubMed. 24(2). 747–136. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026